Best Practices for the Development, Scale-up, and Post-approval Change Control of IR and MR Dosage Forms in the Current Quality-by-Design Paradigm
暂无分享,去创建一个
Matthew Howard | Bruce Thompson | Vinod P. Shah | Mario A. González | Steven Laurenz | Colleen Ruegger | Robert J. Timko | Tapash Ghosh | Ramani R. Raghavan | Angelica Dorantes | Prabir Basu | Avinash G. Thombre | Glenn A. Van Buskirk | Satish Asotra | Christopher Balducci | Gerald DiDonato | W. Mark Eickhoff | Theresa Henry | Jason Kamm | Ryan MacKenzie | Richard Mannion | Patrick K. Noonan | Terrance Ocheltree | Umesh Pai | Richard P. Poska | Michael L. Putnam | Eric Sánchez | Zezhi Jesse Shao | Russell Somma | Vijay Tammara | Satyam Upadrashta | Sivakumar Vaithiyalingam | V. Shah | P. Basu | T. Ghosh | P. Noonan | A. Thombre | R. Timko | Russ Somma | Eric Sánchez | Colleen E. Ruegger | W. Eickhoff | Z. Shao | G. A. Van Buskirk | R. Mannion | S. Vaithiyalingam | S. Asotra | Chris Balducci | A. Dorantes | V. Tammara | Terrance Ocheltree | R. Raghavan | Gerald DiDonato | Theresa Henry | Matthew Howard | Jason Kamm | Steven Laurenz | Ryan MacKenzie | Umesh Pai | R. Poska | M. L. Putnam | Bruce Thompson | Satyam Upadrashta
[1] Roger Nosal,et al. PQLI Key Topics - Criticality, Design Space, and Control Strategy , 2008, Journal of Pharmaceutical Innovation.
[2] Michael Levin,et al. Supac-Mr: Modified Release Solid Oral Dosage Forms—Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls; In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation , 2001 .
[3] Christopher J. Potter,et al. PQLI Roadmap: Product Design, Development, and Realization, a Science- and Risk-Based Approach to Implementation - An Overview of ISPE's First PQLI Guide , 2010 .
[4] F. Theeuwes,et al. Scaleup of Oral Extended-Release Dosage Forms , 2004, Pharmaceutical Research.
[5] Steve Figard,et al. The Basics of Experimental Design for Multivariate Analysis , 2009 .
[6] Keith McDonald,et al. ICH Q11: development and manufacture of drug substances–chemical and biotechnological/biological entities , 2012 .
[7] James Cheney,et al. Quality by design and compression , 2016 .
[8] Michael Levin. Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System , 2001 .
[9] James N. Michaels,et al. Attribute-Based Design Space: Materials-Science-Based Quality-By-Design for Operational Flexibility and Process Portability , 2011, Journal of Pharmaceutical Innovation.
[10] Guidance for Industry PAT — A Framework for Innovative Pharmaceutical Development , Manufacturing , and Quality Assurance , 2004 .
[11] Andre Raw,et al. Quality by Design: Concepts for ANDAs , 2008, The AAPS Journal.
[12] G. E. Peck,et al. Scaleup of Immediate Release Oral Solid Dosage Forms , 2004, Pharmaceutical Research.
[13] Michael Levin,et al. Extended Release Oral Dosage Forms—Development,Evaluation, and Application of In Vitro/In Vivo Correlations , 2001 .
[14] 山田 哲. Guidance for Industry--Changes to an Approved NDA or ANDA , 2004 .